Roivant Sciences Ltd. · NASDAQ:ROIV
Roivant Sciences — Merger or Acquisition (September 2024)
8 slides from Roivant Sciences's merger presentation, Sep 18, 2024
Slide 1: Dermavant Announces $1.2BN Deal with Organon
September 2024 Dermavant Announces $1.2BN Deal with Organon
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical facts
Slide 3: Dermavant Deal Generates Meaningful Additional Capital for Roivant
3 Dermavant Deal Generates Meaningful Additional Capital for Roivant with the Potential for Additional Shareholder Return While Maintaining a Large Share in Potential VTAMA Upside 1. Near-term defined as within the next 3 years. Net of repayment of credit facility which will occur at or before closi
Slide 4: $1.2BN in Potential Payments Across Upfront and Milestones
4 $1.2BN in Potential Payments Across Upfront and Milestones, Plus Additional Upside from Assumed Debt, Cost Savings and Royalties Deal will maximize VTAMA patient reach and value potential as AD launch approaches Note: Under the Merger Agreement, Roivant will receive 100% of payments to equity hold
Slide 5: Our Next Chapter is Anchored by Our Robust Late-Stage Pipeline
5 Our Next Chapter is Anchored by Our Robust Late-Stage Pipeline Note: Pipeline reflects both ongoing clinical trials and expected upcoming trials Represents potentially registrational trials ► For investor audiences only Exciting late-stage pipeline with 6 ongoing registrational trials in multi-bil
Slide 6: 2024 Is a Year of Expansion for Roivant
2024 Is a Year of Expansion for Roivant 6 Note: All timelines reference calendar years Advance Clinical Development In a Range of Underappreciated Pipeline Opportunities Initiate brepocitinib Phase 3 program in NIU and mosliciguat Phase 2 program in PH-ILD; namilumab Phase 2 readout to inform portfo
Slide 7: Multi-Billion $ Value Creation Opportunities Over the Next 2 Years
7 Multi-Billion $ Value Creation Opportunities Over the Next 2 Years Note: Figure is illustrative of potential near-term value creation opportunities and is not intended to be representative of specific dollar values or relative amounts associated with the events noted. All references are to calenda
Slide 8: Thank you.
Thank you. roivant
Roivant Sciences — Merger or Acquisition (September 2024) on 6ix